Review decision - July 2011
TA142 is currently under review. Further information about this review can be found on the Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142) [ID541] appraisals in development page.
Review of NICE Technology Appraisal Guidance no. 142; Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia
The Institute was proposing that a review of the guidance should be planned into NICE’s work programme. The appraisal would be scheduled to coordinate with the availability of results from the EVALUATE study. Three new erythropoietin-analogue products (including two ‘biosimilar’ products) would be included in the appraisal (subject to formal referral from the Department of Health).
During consultation, the majority of comments received by the Institute agreed with the proposal put forward.
After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided that a review of the original guidance should be planned into the NICE work programme.
This page was last updated: 13 July 2012